HNCIG Newsletter

February 2026 edition

The first edition of the HNCIG Newsletter this year is now available - many thanks to Kenya Kobayashi for his work on this.   If you would like to contribute to a future newsletter, please contact the HNCIG secretariat.

New Chair for HNCIG

Appointment announced

The Board of HNCIG is pleased to announce that Professor Sandrdo Porceddu has been appointed Chair of HNCIG.  Professor Porceddu has been a member of TROG for over 20 years and has been a former TROG President and Chair of TROG’s Scientific Committee. The appointment is from 1st September 2026 - with Professor Hisham Mehanna becoming the new CEO of this growing organisation.

HNCIG 2026

Programme now available

The HNCIG Annual Meeting 2026 will be held in Brisbane, Australia on 26th August.  This is the day prior to the IFNOS meeting - and the two meetings will share sessions on 27th August. Registration is free and although the benefits of attending this conference in person are enormous, on-line attendance will also be available. The programme is available here Registration available here

HNCIG - October 2025 Newsletter

HEAD AND NECK CANCER INTERNATIONAL GROUP NEWSLETTER Advert for Co-Chair, Deputy Chair and Members of Communications Group The Communications Group of the Head and Neck Cancer International Group (HNCIG) is seeking members to participate and support the Group. The HNCIG is the umbrella organization for the world’s leading national clinical trials groups in head and neck cancer. As such, HNCIG is the leading global platform for collaborative research in head and neck cancer and is a dynamic and rapidly moving organization with wide...

HNCIG-EPIC-OPC:

PROGNOSTIC IMPLICATIONS OF P16 AND HPV DISCORDANCE: A MULTINATIONAL ANALYSIS, PUBLISHED IN LANCET ON

Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis Read more

HNCIG CONSENSUS ON ENDPOINT DEFINITIONS IN CURATIVE-INTENT TRIALS FOR HNSCC PUBLISHED IN LANCET ONCOLOGY

Read more